These findings suggest that breast cancer has an intrinsically chemoresistant cellular population, defined as CD44+/CD24-, and that anti-HER2 therapy could eradicate this population of cells or CSCs in HER2+ breast cancer. This evidence concerns the gene CD44 and breast carcinoma.